Verastem Oncology (VSTM) Q1 2026 earnings review
Commercial Deceleration While Pipeline Spending Accelerates
Verastem's Q1 2026 results present a stark divergence: the commercial launch of AVMAPKI FAKZYNJA CO-PACK is decelerating rapidly, while pipeline development and associated costs are accelerating. Q1 net product revenue came in at $18.7 million, representing a meager 7% sequential increase from Q4's $17.5 million—a sharp drop-off from the 56% sequential growth seen in the prior quarter. Meanwhile, the company is aggressively expanding its pipeline, initiating three new Phase 2 registration-directed trials for its KRAS G12D inhibitor, VS-7375. This pushed R&D expenses up 31% YoY. With $181.7 million in cash and an operating quarterly burn near $45 million, management maintains a cash runway into H1 2027, but the shrinking commercial growth rate places immense pressure on the pipeline to deliver.
🐂 Bull Case
The KRAS G12D inhibitor program is advancing aggressively. Verastem initiated three Phase 2 registration-directed trials (TARGET-D 201, 202, 203) across pancreatic, non-small cell lung, and colorectal cancers, establishing multiple shots on goal for a massive unmet need.
Updated RAMP 201J data out of Japan showed a 38% overall response rate (and 57% in KRAS-mutated patients), validating the therapy's efficacy overseas and paving the way for regulatory submissions outside the U.S.
🐻 Bear Case
Sequential revenue growth decelerated dramatically from 56% in Q4 to just 7% in Q1. This suggests the initial wave of pent-up demand and warehousing has passed, and reaching peak market penetration will be a much slower, harder grind.
R&D and SG&A expenses combined hit $60.5 million this quarter. With three new Phase 2 trials initiating, expenses will likely accelerate further, threatening the H1 2027 cash runway if commercial revenues plateau.
⚖️ Verdict: ⚪
Neutral. The transition to a broader KRAS G12D pipeline company is promising, but the sudden deceleration in the core commercial asset (AVMAPKI FAKZYNJA CO-PACK) introduces near-term cash flow risk that investors cannot ignore.
Key Themes
Severe Sequential Revenue Deceleration
After a strong start post-approval, AVMAPKI FAKZYNJA CO-PACK sales growth is suddenly decelerating. Revenues grew $6.3 million quarter-over-quarter in Q4 2025, but only grew $1.2 million quarter-over-quarter in Q1 2026. This break in trend is a major red flag for a drug in its first full year of launch. It contradicts management's prior narrative of 'accelerating' momentum and suggests a tougher 'ground war' for new patient starts.
Accelerating R&D Expenditures
Research and development expenses reached $38.2 million in Q1, up 31% YoY. This acceleration is driven by investigator fees, drug manufacturing, and CRO costs associated with launching the three new TARGET-D Phase 2 trials for VS-7375. While necessary for pipeline advancement, this places heavy strain on the balance sheet at a time when commercial revenue growth is slowing.
VS-7375 Broad Phase 2 Initiation
Verastem successfully transitioned its highly anticipated KRAS G12D inhibitor, VS-7375, into three separate registration-directed trials: TARGET-D 201 (PDAC), 202 (NSCLC), and 203 (CRC). This broad-stroke approach maximizes the probability of success across three of the most historically difficult-to-treat solid tumors.
Japan Data Validates Global Opportunity
The RAMP 201J study in Japan continues to be a growth driver for future international expansion. Updated data confirmed a 38% ORR overall, with a highly compelling 57% ORR in patients with KRAS mutations. The safety profile remained consistent with U.S. data, significantly de-risking regulatory pathways in Asia.
Commercial Leadership Shakeup
The company appointed Daniel Lyons as the new Chief Commercial Officer. A CCO transition less than one year into the crucial launch phase of a company's first commercial product often signals internal dissatisfaction with launch trajectories or requires strategic pivots that could temporarily disrupt field execution.
VS-7375 Pharmacokinetics and Dosing Profile
Management reported updated pharmacokinetic (PK) data demonstrating that the 900 mg QD dose achieves optimal target plasma levels and clearly separates from the 600 mg dose. Establishing a clean, well-tolerated higher dose early is a critical differentiator for VS-7375 compared to earlier-generation KRAS inhibitors that struggled with toxicity at therapeutic levels.
Other KPIs
Selling, general & administrative expenses accelerated by 48% YoY (up from $15.0M in Q1 25). This was driven primarily by commercial operations and personnel costs associated with the ongoing U.S. marketing campaign ('Reimagine Recurrent LGSOC').
Improved from a net loss of $52.1M in Q1 2025. However, the non-GAAP adjusted net loss (which removes non-cash warrant liability changes and stock-based compensation) remained effectively flat at $42.7M vs $42.9M a year ago. Operating costs are completely neutralizing the new commercial revenue.
Guidance
Stable. The company ended Q1 with $181.7 million. Management reiterated that this extends runway into H1 2027. However, with GAAP loss from operations at $44.9 million this quarter, achieving this runway depends heavily on either revenue re-accelerating or tight expense controls as new Phase 2 trials ramp up.
Stable. The timeline for early data updates from the Phase 1/2 trial remains on track for the first half of this year, representing the next major value inflection point for the stock.
Stable. The primary endpoint for the Phase 3 confirmatory trial remains scheduled for mid-2027, which will be critical for securing full approval and international expansion.
Key Questions
Drivers of Commercial Deceleration
Sequential revenue growth dropped from 56% to 7%. Is this severe deceleration a result of clearing the initial backlog of warehoused patients, or are you seeing increasing pushback from payers or prescribers in the community setting?
Operating Expense Trajectory
With the initiation of three separate Phase 2 trials (TARGET-D 201, 202, 203), how should we model the sequential increase in R&D expenses for the remainder of 2026? Are current cash runway estimates assuming a cap on enrollment speed?
CCO Transition Strategy
What specific operational changes will Daniel Lyons be implementing to re-accelerate the launch of AVMAPKI FAKZYNJA CO-PACK, and was this leadership change prompted by the slowing Q1 growth metrics?